|
|
Phase II/III Randomized Study of Processed Versus Unprocessed Unrelated Bone Marrow Transplantation in Patients With Acute or Chronic Leukemia or Myelodysplastic Syndromes
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outline Trial Contact Information Registry Information
Alternate Title
Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation
Basic Trial Information
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III, Phase II
|
|
|
|
Supportive care, Treatment
|
|
|
|
Completed
|
|
|
|
12 to 50
|
|
|
|
Other
|
|
|
|
CHIMERIC-HM01 WSU-10-02-99-M01-FB, NCT00004255
|
|
|
Objectives - Compare the efficacy of processed (cell depleted) vs unprocessed (conventional) unrelated bone marrow transplantation in reducing grade III/IV acute graft vs host disease (GVHD) in patients with acute or chronic leukemia or myelodysplastic syndromes.
- Compare the safety of these regimens in these patients.
- Compare the disease-free survival rate at 100 days and at 6 months in patients treated with these regimens.
- Compare the time to engraftment and percent engraftment in patients treated with these regimens.
- Compare the reduction rate of grade II or greater acute and chronic GVHD in patients treated with these regimens.
Entry Criteria Disease Characteristics:
- Diagnosis of one of the following:
- Acute myelogenous leukemia (AML) or acute lymphocytic
leukemia (ALL) in first
early relapse, second remission, or subsequent
remission
- AML in first complete remission with one of the
following adverse features:
- Antecedent hematologic disorder such as
myelodysplasia
- AML resulting from prior chemotherapy or radiotherapy
- More than 1 course of induction chemotherapy to
achieve remission or
adverse cytogenetics such as Philadelphia
chromosome 9:22, +8, +11;
abnormal 12p; or deletions of chromosomes 5, 7, or 20 (3:3)
- ALL in first complete remission with poor risk
cytogenetics such as
- Philadelphia chromosome 9:22, 8:14, or 4:11 OR
- WBC greater than 100,000/mm3
OR - Time to achieve complete remission more than 4
weeks
- Chronic myelogenous leukemia in chronic or accelerated
phase
- Myelodysplastic syndromes
- Refractory anemia with excess blasts (RAEB)
OR - RAEB in transformation
- Unrelated bone marrow donor available
- If matched at 6 of 6 HLA-A, -B, and -DR loci, patient
must be 12 to 50 years
- If matched at 5 of 6 loci, patient must be 12 to 35
years
- No matched sibling donor available
- No uncontrolled CNS leukemia
Prior/Concurrent Therapy:
Biologic therapy: - At least 3 weeks since prior immunotherapy and
recovered
- At least 1 year since prior autologous transplantation
- No prior allogeneic transplantation
Chemotherapy: - See Disease Characteristics
- At least 3 weeks since prior chemotherapy (except hydroxyurea)
and recovered
Endocrine therapy: - At least 3 weeks since prior hormonal therapy and
recovered
Radiotherapy: - See Disease Characteristics
- At least 3 weeks since prior radiotherapy and
recovered
- No prior radiotherapy at doses that would preclude
study
Surgery: Patient Characteristics:
Age: - See Disease Characteristics
- 12 to 50
Performance status: Life expectancy: Hematopoietic: - See Disease Characteristics
Hepatic: - Bilirubin less than 2.5 times upper limit of normal
(ULN)
- SGOT or SGPT less than 2.5 times ULN
Renal: - Creatinine no greater than 1.5 mg/dL
Cardiovascular: - LVEF greater than 50% without medication
Pulmonary: - DLCO and FVC at least 50% predicted
Other: - Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No other serious medical illness
- No uncontrolled diabetes mellitus
- No uncontrolled and/or active infection
- HIV negative
Expected Enrollment A total of 260 patients will be accrued for this study within 17 months. Outline This is a randomized, open-label, multicenter study. Patients are
stratified according to degree of HLA matching and disease (chronic vs acute).
Acute myelogenous leukemia patients are further stratified according to prior
myelodysplastic syndromes (yes vs no). Patients are randomized to one of two
bone marrow transplantation arms. All patients receive a conditioning regimen comprising fludarabine IV
on day -6, cyclophosphamide IV on days -5 and -4, anti-thymocyte globulin IV
on days -4 and -2, and total body irradiation on days -3 to 0. Patients also
receive methylprednisolone IV every 12 hours for 4 doses on days -2 to 0.
Tacrolimus IV is administered continuously on day -1 and continues either
orally or IV for 6 months. Bone marrow is infused on day 0. Filgrastim
(G-CSF) is administered subcutaneously from day 0 until blood counts
recover. - Arm I: Patients receive allogeneic bone marrow that has been processed
to produce a mononuclear cell preparation.
- Arm II: Patients receive unprocessed allogeneic bone marrow.
Patients are followed weekly for 100 days and then at 6 months.
Trial Contact Information
Trial Lead Organizations Chimeric Therapies Incorporated | | | James N. Lowder, MD, Protocol chair(Contact information may not be current) | | | |
Registry Information | | Official Title | | A Multi-Center, Open Label, Randomized, Active Controlled Phase II/III Clinical Trial to Evaluate the Safety and Efficacy of Processed Unrelated Bone Marrow in Patients with Acute or Chronic Leukemia | | Trial Start Date | | 2000-03-16 | | Registered in ClinicalTrials.gov | | NCT00004255 | | Date Submitted to PDQ | | 2000-01-03 | | Information Last Verified | | 2002-02-25 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
|